Cardinal Health Inc (CAH)
Official siteHEALTHCARE • MEDICAL DISTRIBUTION • NYSE
Market Cap: $64.97B
Last updated: Nov 17, 2026 at 11:05 AM ET
Cardinal Health Inc (CAH) Earnings: Report Dates and Results
Cardinal Health (CAH) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Cardinal Health reported EPS of $3.26, above the $2.92 estimate. It beat the EPS estimate in each of the last 17 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CAH has an expected report date of Feb 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 19.0% above the $2.63 reported for the quarter ended Dec 31, 2025.
CAH Earnings Call
The latest CAH earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CAH beat 34 and missed 6. Revenue for the quarter ended Sep 30, 2026 was $67.51B, up 5.5% from $64.01B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $3.26 | $2.92 | $2.88 - $3.06 | +11.64% | Beat | +27.8% | 13 | 4 up, 3 down | Nov 5, 2026 | $67.51B |
| Jun 30, 2026 | $2.91 | $2.42 | N/A | +20.25% | Beat | +39.9% | 15 | 3 up, 0 down | Aug 11, 2026 | $63.67B |
| Mar 31, 2026 | $3.17 | $2.79 | $2.67 - $3.01 | +13.62% | Beat | +34.9% | 15 | 3 up, 1 down | Apr 30, 2026 | $60.94B |
| Dec 31, 2025 | $2.63 | $2.37 | $2.31 - $2.46 | +10.97% | Beat | +36.3% | 11 | 9 up, 0 down | Feb 5, 2026 | $65.63B |
| Sep 30, 2025 | $2.55 | $2.17 | $2.10 - $2.42 | +17.51% | Beat | +35.6% | 14 | N/A | Oct 30, 2025 | $64.01B |
| Jun 30, 2025 | $2.08 | $2.03 | N/A | +2.46% | Beat | +13.0% | 15 | 12 up, 0 down | Aug 12, 2025 | $60.16B |
| Mar 31, 2025 | $2.35 | $2.15 | $1.93 - $2.22 | +9.30% | Beat | +13.0% | 13 | N/A | May 1, 2025 | $54.88B |
| Dec 31, 2024 | $1.93 | $1.76 | $1.46 - $1.88 | +9.66% | Beat | +6.0% | 13 | 2 up, 1 down | Jan 30, 2025 | $55.26B |
| Sep 30, 2024 | $1.88 | $1.62 | $1.54 - $1.76 | +16.05% | Beat | +8.7% | 15 | 1 up, 0 down | Nov 1, 2024 | $52.28B |
| Jun 30, 2024 | $1.84 | $1.73 | $1.70 - $1.77 | +6.36% | Beat | +18.7% | 14 | 1 up, 0 down | Aug 14, 2024 | $59.87B |
| Mar 31, 2024 | $2.08 | $1.95 | $1.89 - $2.02 | +6.67% | Beat | +19.5% | 14 | 0 up, 2 down | May 2, 2024 | $54.87B |
| Dec 31, 2023 | $1.82 | $1.60 | $1.50 - $1.74 | +13.75% | Beat | +37.9% | 13 | 2 up, 0 down | Feb 1, 2024 | $57.44B |
| Sep 30, 2023 | $1.73 | $1.41 | $1.34 - $1.49 | +22.70% | Beat | +44.2% | 11 | 0 up, 2 down | Nov 3, 2023 | $54.65B |
| Jun 30, 2023 | $1.55 | $1.48 | $1.46 - $1.54 | +4.73% | Beat | +47.6% | 13 | 1 up, 0 down | Aug 15, 2023 | $53.42B |
| Mar 31, 2023 | $1.74 | $1.49 | $1.45 - $1.56 | +16.78% | Beat | +20.0% | 14 | 2 up, 0 down | May 4, 2023 | $50.49B |
| Dec 31, 2022 | $1.32 | $1.14 | $1.06 - $1.21 | +15.79% | Beat | +3.9% | 11 | 2 up, 0 down | Feb 2, 2023 | $51.47B |
| Sep 30, 2022 | $1.20 | $0.97 | $0.89 - $1.04 | +23.71% | Beat | -7.0% | 11 | 0 up, 2 down | Nov 4, 2022 | $49.60B |
| Jun 30, 2022 | $1.05 | $1.18 | $1.13 - $1.20 | -11.02% | Miss | +36.4% | 11 | 1 up, 0 down | Aug 11, 2022 | $47.06B |
| Mar 31, 2022 | $1.45 | $1.53 | $1.42 - $1.64 | -5.23% | Miss | -5.2% | 12 | 1 up, 1 down | May 5, 2022 | $44.84B |
| Dec 31, 2021 | $1.27 | $1.23 | $1.11 - $1.32 | +3.25% | Beat | -27.0% | 12 | N/A | Feb 3, 2022 | $45.46B |
| Sep 30, 2021 | $1.29 | $1.35 | $1.26 - $1.41 | -4.44% | Miss | -14.6% | 10 | N/A | Nov 9, 2021 | $43.97B |
| Jun 30, 2021 | $0.77 | $1.20 | $1.13 - $1.22 | -35.83% | Miss | -26.0% | 12 | N/A | Aug 5, 2021 | $42.59B |
| Mar 31, 2021 | $1.53 | $1.56 | $1.47 - $1.76 | -1.92% | Miss | -5.6% | 14 | N/A | May 6, 2021 | $39.27B |
| Dec 31, 2020 | $1.74 | $1.45 | $1.40 - $1.49 | +20.00% | Beat | +14.5% | 15 | N/A | Feb 5, 2021 | $41.54B |
| Sep 30, 2020 | $1.51 | $1.14 | $1.09 - $1.16 | +32.46% | Beat | +18.9% | 16 | N/A | Nov 5, 2020 | $39.06B |
| Jun 30, 2020 | $1.04 | $0.89 | $0.71 - $1.13 | +16.85% | Beat | -6.3% | 14 | N/A | Aug 6, 2020 | $36.69B |
| Mar 31, 2020 | $1.62 | $1.45 | $1.16 - $1.55 | +11.72% | Beat | +1.9% | 14 | N/A | May 11, 2020 | $39.16B |
| Dec 31, 2019 | $1.52 | $1.22 | $1.15 - $1.29 | +24.59% | Beat | +17.8% | 13 | N/A | Feb 6, 2020 | $39.73B |
| Sep 30, 2019 | $1.27 | $1.09 | $1.04 - $1.14 | +16.51% | Beat | -1.6% | 15 | N/A | Nov 7, 2019 | $37.34B |
| Jun 30, 2019 | $1.11 | $0.94 | $0.87 - $0.99 | +18.09% | Beat | +9.9% | 15 | N/A | Aug 8, 2019 | $37.35B |
| Mar 31, 2019 | $1.59 | $1.41 | $1.30 - $1.54 | +12.77% | Beat | +14.4% | 16 | N/A | May 9, 2019 | $35.23B |
| Dec 31, 2018 | $1.29 | $1.09 | $1.01 - $1.15 | +18.35% | Beat | -14.6% | 15 | N/A | Feb 7, 2019 | $37.74B |
| Sep 30, 2018 | $1.29 | $1.07 | $1.01 - $1.20 | +20.56% | Beat | +18.3% | 16 | N/A | Nov 8, 2018 | $35.21B |
| Jun 30, 2018 | $1.01 | $0.93 | $0.89 - $0.97 | +8.60% | Beat | -22.9% | 17 | N/A | Aug 6, 2018 | $35.35B |
| Mar 31, 2018 | $1.39 | $1.51 | $1.45 - $1.57 | -7.95% | Miss | -9.2% | 17 | N/A | May 3, 2018 | $33.63B |
| Dec 31, 2017 | $1.51 | $1.16 | $1.09 - $1.29 | +30.17% | Beat | +12.7% | 16 | N/A | Feb 8, 2018 | $35.19B |
| Sep 30, 2017 | $1.09 | $1.00 | $0.96 - $1.06 | +9.00% | Beat | -12.1% | 13 | N/A | Nov 6, 2017 | $32.64B |
| Jun 30, 2017 | $1.31 | $1.24 | $1.22 - $1.26 | +5.65% | Beat | +14.9% | 17 | N/A | Aug 2, 2017 | $32.97B |
| Mar 31, 2017 | $1.53 | $1.46 | N/A | +4.79% | Beat | +7.0% | N/A | N/A | May 1, 2017 | $31.82B |
| Dec 31, 2016 | $1.34 | $1.23 | N/A | +8.94% | Beat | +3.1% | N/A | N/A | Feb 7, 2017 | $33.15B |
Annual EPS
EPS for the fiscal year ended Jun 30, 2026 was $11.26, up 36.7% from the year before. It was $5.42 for the year ended Jun 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Jun 30, 2026 | $11.26 | +36.7% |
| Jun 30, 2025 | $8.24 | +10.3% |
| Jun 30, 2024 | $7.47 | +28.6% |
| Jun 30, 2023 | $5.81 | +14.8% |
| Jun 30, 2022 | $5.06 | -8.8% |
| Jun 30, 2021 | $5.55 | +1.8% |
| Jun 30, 2020 | $5.45 | +3.2% |
| Jun 30, 2019 | $5.28 | +5.6% |
| Jun 30, 2018 | $5.00 | -7.7% |
| Jun 30, 2017 | $5.42 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,700 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,701 | 17 | |
| 2026Q2 | Jun 30, 2026 | 10,063 | 18 | |
| 2026Q1 | Mar 31, 2026 | 7,370 | 15 | |
| 2025Q4 | Dec 31, 2025 | 8,721 | 17 | |
| 2025Q3 | Sep 30, 2025 | 8,607 | 18 | |
| 2025Q2 | Jun 30, 2025 | 10,723 | 16 | |
| 2025Q1 | Mar 31, 2025 | 3,278 | 8 | |
| 2024Q4 | Dec 31, 2024 | 10,668 | 16 |
2026Q3 Earnings Call
Opening remarks
Matt Sims Vice President, Investor Relations Good morning, and welcome to Cardinal Health's Third Quarter Fiscal '26 Earnings Conference Call, and thank you for joining us. With me today are Cardinal Health's CEO, Jason Hollar; and our CFO, Aaron Alt. You can find this morning's earnings press release and investor presentation on the Investor Relations section of our website at ir.cardinalhealth.com. Since we will be making forward-looking statements today, let me remind you that the matters addressed in these statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected or implied. Please refer to our SEC filings and the forward-looking statement slide at the beginning of our presentation for a description of these risks and uncertainties. Please note that during our discussion today, the comments will be on a non-GAAP basis, unless specifically called out as GAAP. GAAP to non-GAAP reconciliations for all relevant periods can be found in the supporting schedules attached to our press release. For the Q&A portion of today's call, we kindly ask that you limit questions to one per participant so that we can try and give everyone an opportunity. With that, I will now turn the call over to Jason.
Jason Hollar Chief Executive Officer Thanks, Matt, and good morning, everyone. We are pleased to report another strong quarter for Cardinal Health, building on the momentum we displayed over the past few years. This quarter's performance highlights the durability and resilience of our business and the team's disciplined execution. The results reinforce our conviction in the company's growth trajectory and ability to deliver long-term value creation. Our underlying operating strength continues to be led by our largest and most significant business Pharmaceutical and Specialty Solutions, and is amplified by contributions from our higher-margin growth businesses. Within Pharma, we delivered strong growth, highlighting the strength of our core. We continue to see benefits from our strategic focus on expanding our capabilities across Specialty, both downstream of providers and upstream with manufacturers. We are progressing the expansion of our MSO platforms, in particular with the Specialty Alliances multi-specialty offerings, delivering differentiated value to a growing network of physicians and enhancing patient care and access. The integration of Solaris into the Specialty Alliance remains on track, and we are taking actions to realize synergistic benefits across our portfolio. In GMPD, we continue to execute against our improvement plan. Our focus on simplification and cost optimization initiatives is producing tangible results, and we continue to see notable strength in our portfolio of Cardinal Health brand products. Our deliberate actions to simplify operations, enhance supply chain resiliency and drive commercial excellence remain strategic priorities as the business navigates the dynamic tariff environment.
Frequently Asked Questions About CAH
When is Cardinal Health's next earnings date?
Cardinal Health's next earnings report is expected for Feb 3, 2027.
Did CAH beat earnings estimates last quarter?
Yes. Cardinal Health reported EPS of $3.26 for the quarter ended Sep 30, 2026, above the $2.92 estimate, a 11.64% surprise.
What EPS do analysts expect from CAH next quarter?
The consensus EPS estimate for Cardinal Health for the quarter ending Dec 31, 2026 is $3.13 from 10 analysts, with estimates from $2.93 to $3.64.
How often does CAH beat earnings estimates?
Cardinal Health beat the EPS estimate in each of the last 17 quarters, with an average surprise of +13.06%.
CAH pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts